Page 151 - Binder2

of modern oncology, the frontier of gene and cell therapy.
And yet, the category carries a vulnerability it can no
longer afford to ignore:
It’s burning trust faster than it’s earning durability.

Because a therapy that fails after 12 months is not a
solution.
It’s an expensive stall tactic.

To be sustainable, biologics must evolve into long-term
infrastructure—not one-time interventions, not repeat
cycles of hope and disappointment.

This isn’t just about today’s disease burden.
It’s about tomorrow’s breakthroughs—in oncology,
neuroimmunology, organ transplantation, metabolic
modulation, even tolerance-based vaccines.
All of these emerging frontiers depend on immune
cooperation, not brute-force suppression.
And as the science gets more complex, the immune
system’s role becomes more central—not peripheral.

The more advanced the therapy, the less room there is for
immune rejection.
You can’t afford to trigger anti-drug antibodies in a CAR-T
construct.
You can’t escalate dosing on a gene-editing payload.
You can’t rotate out of a one-time biologic meant to induce
immune reset.

Precision fails without permanence.
And permanence requires immune acceptance.

At the same time, healthcare systems around the world are
reaching a fiscal breaking point.
As biologic pricing continues to rise—and as biologic

149